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Abstract
Both  Rheumatoid  Arthritis  (RA)  and  atherosclerosis  are  complex  polygenic  diseases.  Previous  studies  have 
demonstrated that patients with RA are associated with up to 60% increased risk of cardiovascular disease related 
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Introduction
Rheumatoid Arthritis (RA) is a chronic inflammatory disease, which 
affects 0.51% of the population in the world [1-3]. RA is characterized 
by a systemic inflammatory state, involving several organs, including 
joints, skin, eyes, lung and blood vessels [4]. Patients with conditions 
such as RA are associated with an increase mortality compared with the 
general population [5]. A major part of the excess mortality has been 
attributed to cardiovascular disease (CVD) [5,6]. The results of a recent 
systematic review showed that RA is associated with a 60% increase in 
the risk of CVD-related death [7]. In particular, inflammation in RA is 
now considered as an independent risk factor for the development of 
atherosclerosis [8]. Both RA and atherosclerosis are complex polygenic 
diseases with shared disease mechanism. There is increasing evidence 
that chronic inflammation and immune dysregulation contributes to 
accelerated atherogenesis and plays a role in all stages of atherosclerosis 
(i.e., atherogenesis, atheroma progression, and the development of 
thrombosis) [7]. Further, the increased cardiovascular morbidity 
and mortality in patients with RA cannot be entirely explained by 
traditional risk factors, such as type 2 diabetes mellitus, Metabolic 
Syndrome (MetS) and smoking habit. This article reviews the data 
supporting the association of RA with CVD, the possible mechanism 
for atherosclerosis, and discusses potential strategies for the prevention 
of atherosclerosis in such patients.
Mortality and mortality of RA is related to atherosclerosis
Large epidemiological studies from the last few decades have 
confirmed that patients with RA are 60% more likely to suffer a CV event 
than subjects from the general population [7]. The major complication 
in patients with RA is the development of cardiovascular events due 
to accelerated atherosclerosis. A recent Dutch, cross-sectional study 
found that age- and gender-adjusted odds ratios for CV diseases 
derived from these cohorts were 3.1 for patients with RA. Further, up to 
13% non-diabetic RA patients developed CVD (coronary, cerebral and 
peripheral arterial diseases) [9]. Multiple studies have confirmed that 
the excess mortality in RA is largely attributed to CV death. A recent 
meta-analysis of 24 studies showed a 50% increased risk of CV death 
overall [10]. RA patients have a 2 to 3 fold risk of myocardial infarction, 
a 2 fold risk of congestive heart failure, a 2 increase risk of sudden death 
and a 1.7 fold increased risk of strokes [11-14]. Accordingly, clinicians 
should be aware of the high risk and provide close surveillance of CVD 
in patients with RA. 
Subclinical Atherosclerosis 
Carotid intima-media thickness
An approach to assess the presence and extent of subclinical 
atherosclerosis is carotid ultrasonography. In the general population, 
carotid ultrasound has been used for cardiovascular risk stratification; 
Intimal-Medial Thickness (IMT) and plaque are associated with clinical 
CVD and have independent prognostic value for such CV events [14]. 
In 2 studies of Asian patients [15,16] and in a study from Poland 
[17],  carotid IMT was increased in patients with RA compared with 
matched controls. In addition, patients with RA had a similar carotid 
IMT and prevalence of carotid plaque as with age- and gender-matched 
patients with type 2 diabetes mellitus. The result thus suggested that 
both diseases contribute equally to the development of premature 
atherosclerosis [18]. A meta-analysis was performed involving 22 
studies to estimate the overall mean carotid IMT difference between 
RA and control groups [19].  In 17 of the studies, patients with RA 
had a statistically significantly greater carotid IMT. The overall mean 
carotid IMT difference was 0.09 mm, indicated an approximately 15% 
increased cardiovascular risk [20]. However, this was not confirmed 
by a study from the United States, showing no significant difference 
in carotid IMT and carotid plaque between patients with RA and 
control [21]. Nonetheless, carotid IMT was correlated positively 
with inflammatory markers both in patients with RA and controls, 
suggesting that systemic inflammation played a significant role in the 
development of atherosclerosis. 
The presence of carotid plaques is a more reliable predictor of 
cardiovascular events than IMT [22]. In a cross-sectional study of 
98 patients with RA, Salmon and Roman [23] demonstrated that the 
presence of carotid atherosclerotic plaques was greater than controls 
(44% vs. 15%, p<0.01). The same result was similarly shown by and 
Stamatelopoulos and colleagues [18] (48% vs. 10%, p<0.01). The 
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clinical importance for the presence of carotid plaque, but not carotid 
IMT, was demonstrated by a study involving 105 patients with RA, that 
demonstrated patients with bilateral carotid plaques were associated 
with a worse CVD event survival (Hazard ratio = 6.31) [24]. These 
result confirmed that RA is strongly associated with atherosclerosis 
development in the carotid arteries that could explain for the high 
stroke incidence in these patients.
Coronary artery calcification
Coronary Arterial Calcification (CAC), as a subclinical measure 
of atherosclerosis, measured by Computed Tomography (CT), is 
closely associated with the degree of atherosclerotic plaque [25], and 
is strongly predictive of cardiovascular events [26,27]. In a report by 
Chung and colleague, patients with early RA or established RA had 
a significantly higher prevalence of CAC than non-RA controls (43% 
vs. 61% vs. 38%, respectively, p=0.016) [28]. Moreover, patients with 
longstanding RA have been shown to be associated with a higher CAC, 
suggesting that disease duration may be an important factor related 
to coronary atherosclerosis [29]. In a study by Giles et al., increasing 
severity of RA was associated with a high prevalence and extent of 
coronary calcification, irrespective of gender and age. Interestingly, 
these association was attenuated after adjusting for IL-6, thus suggest 
that systemic inflammation was important to the development of 
coronary atherosclerosis [28]. Another study by Wang and colleagues 
has further demonstrated that patients with RA had earlier onset, more 
diffuse arterial calcification over multiple vascular beds and more 
preferential involvement of thoracic aorta, rather than coronary artery 
compared with control [29].
Microcirculation disorder
The endothelium is the innermost lining of the vasculature and 
its integrity is crucial to maintain vascular hemostasis. Damage 
to the endothelium can cause endothelial dysfunction, which 
is an early indicator for CVD [30]. As endothelial dysfunction 
may occur differentially in different vascular beds, in particular, 
microvascular dysfunction may occur in addition to macrovascular 
dysfunction. A study involving 99 RA patients evaluated the relation 
between microvascular function using laser Doppler imaging, 
with macrovascular vasodilatory function [31]. It was shown that 
both microvascular and macrovascular endothelial function were 
independent of each other in patients with RA, suggesting differential 
regulation of endothelial function in these two vascular beds. Indeed, 
microvascular dysfunction has been previously described in patients 
with RA [32,33]. In 65 female RA patients, cutaneous microcirculatory 
function, assessed by laser Doppler imaging, was reduced compared 
with controls [34]. Similarly, a study by Datta et al. [33] demonstrated 
that among 8 RA patients, cutaneous microvascular function was 
impaired and subsequently improved following treatment of disease 
[35]. Another recent study demonstrated 12/18 RA patients had 
myocardial ischemia by dobutamine stress contrast echocardiography. 
Interestingly, 8 of these patients underwent invasive coronary 
angiogram of which 4 had normal coronary vessels, 2 had non-flow 
limiting coronary lesions and the remaining had significant coronary 
atherosclerosis. This results suggested that microvascular abnormalities 
may account for myocardial ischemia as evidenced by absence of 
significant coronary occlusion in a significant number of patients 
[36]. Accordingly, these studies highlighted that atherosclerosis is not 
limited to plaque formation in large conduit vessels but also disturb 
function in smaller resistance vessels, that is key in regulating tissue 
perfusion, including myocardial perfusion. 
Mechanism of Premature Atherosclerosis
The pathogenesis of atherosclerosis is likely multifactorial, 
including clustering of traditional cardiovascular risk factors, 
inflammatory mediated and genetic factors (Figure 1) [37]. 
The cardiovascular risk factors for atheroscleroTraditional 
risk factors
Traditional risk factors for vascular disease, such as smoking, 
hypertension, diabetes and hyperlipidemia are important, but cannot 
fully account for, the increased risk of CVD in RA [38]. In a study by 
Chung et al., 197 patients with RA were compared with 274 frequency-
matched control subjects [39]. It was found that 80% of patients with 
RA and 81% of control subjects had at least 1 modifiable traditional 
cardiovascular risk factor. Hypertension was more prevalent in the RA 
group (57%) than in controls [42%, p=0.001]. However, there were no 
statistically significant differences in the frequency of diabetes, elevated 
body mass index, smoking, intermediate-high 10-year coronary heart 
disease risk, or elevated LDL in patients with RA versus controls. 
Moreover, rates of newly identified diabetes, hypertension, and 
hyperlipidemia were similar in RA patients versus controls. 
(i)	 Metabolic syndrome: Metabolic syndrome (MetS) is a 
cluster of traditional risk factors (including hypertension, diabetes, 
dyslipidemia and central obesity) that increase the risk of cardiovascular 
events. The most commonly used definitions for the diagnosis of MetS 
include the WHO criteria and the National Cholesterol Education 
Program Adult Treatment Panel (NCEP) III criteria. Both of these 
definitions involve the assessment of fasting glucose, dyslipidemia, 
hypertension and central obesity. Indeed, MetS is a common 
presentation in patients with rheumatic diseases and represents an 
important risk for developing atherosclerosis. 
A study by da Cunha et al. involving 283 patients with RA and 226 
controls demonstrated that the risk of having MetS was significantly 
higher in RA patients than controls [odds ratio (OR) =1.9, p<0.01] and 
was associated with disease activity [40]. Further, MetS has been shown 
to be more prevalent in patients with long-standing RA or early RA 
than in non-RA controls (WHO criteria: 42% versus 31% versus 11%, 
respectively, P<0.001; NCEPIII criteria: 42% versus 30% versus 22%, 
p=0.03) [41]. Another study evaluated the prevalence of MetS in 200 
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non-RA controls in the Mediterranean region. Although the overall 
prevalence of MetS was similar between both patient groups (44% 
versus 41%, p=0.5), those with RA who had MetS were more likely to 
have high RA disease activity (DAS28 >3.2) than those without MetS 
[42]. In addition, individual cardiovascular risk factors contributed 
to carotid IMT thickness in a study that involved 631 patients with 
RA [43]. Data from the Consortium of Rheumatology Researchers 
of North America registry demonstrated that increased markers of 
severity of RA, in addition to conventional CVD risk factors, were 
associated with an increase in cardiovascular risk. In particular, 
patients with absence of risk factors or markers of RA severity did not 
develop any cardiovascular events. In contrast, patients with at least 
two traditional CVD risk factors and three or more markers of RA 
severity had an incidence rate of 7.47 (per 1,000 person-years) [44]. 
These data thus suggest that conventional CVD risk factors and MetS 
are both associated with the development of premature atherosclerosis 
in RA. 
Endothelial progenitor cells
Atherosclerosis is an inflammatory condition which starts as 
a “response to injury” favoring endothelial dysfunction which is 
associated with increased expression of adhesion molecules, pro-
inflammatory cytokines, pro-thrombotic factors, oxidative stress 
upregulation and abnormal vascular tone modulation. Endothelial 
dysfunction in rheumatic autoimmune diseases involves innate immune 
responses, including macrophages and dendritic cells expression of 
scavenger and toll-like receptors for modified or native LDL as well as 
neutrophil and complement activation, and dysregulation of adaptive 
immune responses, including proliferation of autoreactive T-helper-1 
lymphocytes and defective function of dendritic and regulatory T cells 
[45]. As previously pointed out by Kitas and Gabriel, classic CV risk 
factors are important but not sufficient to explain all of the CV excess 
risk found in RA [46]. Endothelial dysfunction is an early step in the 
atherogenesis process of RA. More experiments have showed that 
microvascular endothelial function is a better predictor of CV outcome 
than macrovascular endothelial function in patients with RA [47,48].
Vasculogenesis is the generation of vessels from Endothelial 
Progenitor Cells (EPCs). Vasculogenesis may also be linked to 
atherosclerosis in RA [49]. Stimulation of EPCs and vasculogenesis 
may be beneficial to prevent and manage atherosclerosis related to 
arthritis [50].
The study by Yiu et al. demonstrated that RA patients with 
coronary atherosclerosis have significantly lower levels of CD133/
KDR+ and CD133+ EPC than those without. In addition to older age, 
lower levels of circulating CD133/KDR+ EPC also predicted occurrence 
of coronary atherosclerosis in RA patients [51]. The result of this 
study thus confirmed that EPCs is closely associated with coronary 
atherosclerosis in this group of patients. While measures that may 
increase EPCs and provide protection for premature atherosclerosis 
would however require future studies for evaluation. 
Chronic inflammation and immune dysregulation of RA and 
atherosclerosis
Conventional cardiovascular risk factors may not fully account for 
the difference in risk of CVD between patients with RA and the general 
population. Systemic inflammation is one of the pivotal pathogenetic 
principles in atherogenesis and progression of atherosclerosis. 
Accordingly, RA-related systemic inflammation, may contribute to the 
observed gap [52]. 
In patients with RA, a raised baseline C-reactive protein (CRP) 
level is an independent predictor for cardiovascular mortality, which 
means reduction of inflammatory activity may reduce cardiovascular 
morbidity and mortality [53]. Further, inflammatory disorders, 
characterized by high levels of CRP, can develop a secondary immune 
cell activation, which may result in atherogenesis [54]. In addition, 
studies have demonstrated that inflammatory related markers such as 
lipoproteins, ox-LDLs [55], NO [55], TNF-a [56], RANKL [57], CD40L 
[58], IL-18 [59], MMP-9 [60], MCP-1[61], insulin [45], EPCs [51] in 
atherosclerosis are altered in patients with RA. These evidences thus 
support the theory that systemic inflammation plays a crucial role in 
the pathogenesis of CVD in patients with RA.
Genetic influence in the development of CV disease in 
patients with RA
Both RA and atherosclerosis display a strong genetic component of 
susceptibility [52]. RA has an estimated heritability of up to 60% [62] 
and CV disease in the general population of up to 30–60% [63]. Besides, 
a specific genetic background may contribute to the development of 
both diseases. The chemokine CCL21 has also been implicated in the 
pathogenesis of both RA and atherosclerosis [34,35]. A polymorphism 
from this gene (rs2812378) was associated to a higher CV and all-
causes mortality risk, in a UK chronic arthritis, including RA, cohort. 
The plasminogen activator inhibitor type 1 (PAI-1) is the primary 
physiologic inhibitor of plasminogen activation in blood [64]. PAI-1 
overexpression may compromise normal fibrin clearance mechanisms 
and promote pathological fibrin deposition and thrombotic events. A 
polymorphism of this gene, located in the promoter region (at starting 
position –675, 4G/5G), has previously been associated to CV disease 
and venous thrombotic episodes [65] in the general population. In 
patients with RA, this variant, together with TNFRII and FXIIIA, have 
also been associated with CVD in a cohort of Sweden patients [66]. 
Atherosclerosis and Rheumatoid Arthritis Therapies 
Corticosteroids
Corticosteroids are often used in the treatment of SLE, RA, and 
other inflammatory disorders. High dose treatment with corticosteroids 
has adverse effects on the cardiovascular system, including endothelial 
dysfunction, hypertension and dysregulated glucose metabolism [67]. In 
a population-based cohort (n=603), Rheumatoid Factor (RF)-positive 
patients were at increased risk of cardiovascular events following 
exposure to glucocorticoids, but not RF-negative patients [68]. The 
influence of low-dose prednisolone on atherosclerosis, endothelial 
function, and risk factors for atherosclerosis in patients with early RA 
was studied by Hafström [69,70]. These studies demonstrated that low-
dose prednisolone (less than 7.5 mg daily) did not influence endothelial 
function and atherosclerosis in patients with RA. The mechanisms 
causing the potential interaction between corticosteroid exposure and 
premature atherosclerosis should be evaluated in future researches.
Statin
Statins (3-hydroxy-3-methylglutarylcoenzyme-A reductase 
inhibitors) reduce CVD morbidity and mortality in at-risk patients 
[71]. The anti-inflammatory and immunomodulating effects of statins 
include suppression of leukocyte cytokine release, reduced MHC class 
II expression and reduced production of reactive oxygen species [72]. 
A recent population-based longitudinal study demonstrated that statin 
discontinuation is associated with an increased risk of CVD related 
death (Relative risk=1.79) [73]. Apart from reducing lipid levels, 
treatment with statin in patients with RA may also have a modest but 
clinically useful effect on arthritis. Atorvastatin has also been shown to 
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reduce arterial stiffness in patients with RA and high disease activity 
[74] (Table 1). Further, it was shown that aortic PWV and flow 
mediated dilatation (FMD) was significantly improved upon treatment 
with atorvastatin or ezetimib [75]. In a study by Hermann et al., it was 
shown that statin therapy improves vascular function measured by 
FMD [76]. Another study involving 50 RA patients were randomized in 
a double-blind placebo-controlled trial in receiving 10 mg rosuvastatin 
(n=24) or placebo (n=26) [77]. It was shown that rosuvastatin has a 
modest anti-inflammatory effect in patients with RA and low disease 
activity in terms of reduction in DAS and fibrinogen level, but not 
arterial stiffness or carotid IMT. Accordingly, statin-related reduction 
in inflammatory biomarkers provided the rationale for a randomized 
controlled trial of atorvastatin for treatment of synovitis in RA (the 
Trial of Atorvastatin in Rheumatoid Arthritis [TARA]) [78]. 
Methotrexate and atherosclerosis
Methotrexate (MTX) is the first-choice DMARD in patients RA. 
Its mechanisms of action are diverse and complex but in the doses 
used to treat RA, its actions are likely to be anti-inflammatory. The 
anti-inflammatory effects of MTX in RA may thus prevent premature 
development of atherosclerosis. In a cohort of 1240 patients with RA, 
it was shown the MTX provided survival benefit mainly by reducing 
cardiovascular mortality (relative risk=0.3) during a mean of 6 years 
follow up [79]. Similarly, other studies have demonstrated that MTX 
therapy is associated with a reduction of cardiovascular morbidity 
and mortality, ranging from 15% to 85% [80-82]. In addition, 2 
small studies have shown statistically significant reductions in 
carotid IMT with combination MTX plus chloroquine therapy [83] 
and combination MTX plus prednisolone therapy [84] but have not 
assessed the effect of MTX alone. However, the beneficial effect of MTX 
therapy in the preventing preclinical atherosclerosis was not confirmed 
in another study [15]. Nonetheless, randomized study to evaluate the 
cardiovascular protective effect of MTX in patients with RA would be 
required. 
Biologics therapy and atherosclerosis
The cytokine tumour necrosis factor α (TNFα) is key in the 
pathogenesis of RA [85]. Theoretically, anti-TNFα will, by reducing 
inflammation and improving arthritis, may also decrease the burden 
of CVD. Accordingly, a number of studies using anti-TNFα, such 
as infliximab, etanercept, adalimnumab, attempted to evaluate its 
cardioprotective in patients with RA. In a prospective observation study 
by Dixon et al., it was shown that patients with RA who respond to 
anti-TNFα therapy (n=5877) had a lower risk of myocardial infarction 
(relative risk=0.38) compared with non-responders (n=1638) [86]. In 
contrast, in a recent cohort study (n=6000), neither treatment with nor 
response to anti-TNFα reduced the risk of acute coronary syndrome 
within the first year of diagnosis of RA, which may be explained by the 
differences in the burden of disease [87].
In an early report, Hürlimann et al. demonstrated that anti-TNFα 
therapy improves endothelial function in patients with RA (Table 1) 
[88]. In a post hoc analysis of longitudinal data from a randomized 
placebo controlled study also showed that infliximab therapy was 
associated with an improvement of arterial stiffness as measured by 
pulse wave velocity (PWV), but not carotid IMT and carotid artery 
plaque, in patients with RA (n=26) [89]. Further, 1-year treatment 
with anti-TNFα therapy has been shown to improve both PWV 
and carotid IMT in patients with inflammatory arthropathies [90]. 
However in another study, despite significant reduction in synovitis 
and inflammatory markers, 6 weeks of anti-TNF α therapy did not 
improve arterial stiffness [91]. The effect of anti-rheumatic treatment 
on microvascular endothelial function in 51 patients with active RA and 
no previous history of cardiovascular disease was assessed by Galarraga 
[92]. It was found that both endothelium-dependent and independent 
responses did not improve significantly after treatment with biologics 
or methotrexate therapy. However, patients who responded to anti-
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endothelium-dependent and independent responses. This study thus 
suggested that tight and aggressive control of RA disease activity may 
protect CVD in addition to joint damage and disability. In a recent 
open-label study in patients with early RA, PWV was compared 
between methotrexate (MTX) alone and MTX plus infliximab 
(n=20 each arm) [93]. The result showed that MTX plus infliximab 
significantly reduced PWV compared with MTX alone. A more recent 
study further demonstrated that aortic inflammation can be reduced 
by anti-TNFα detected by aortic (18)F-fluorodeoxyglucose positron 
emission tomography with computed tomography coregistration [94]. 
Moreover, the reduction of aortic inflammation is associated with 
concomitant improvements in endothelial function, inflammatory 
markers and aortic stiffness. These studies thus suggested that use of 
anti-TNFα therapy improves cardiovascular surrogate markers and 
protect the development of premature atherosclerosis in RA patients. 
In addition to anti-TNFα, interleukin (IL)-6 is also an important 
factor that regulates the immune response, inflammation and 
hematopoiesis. Blocking IL-6 actions by tocilizumab, a humanized 
antibody has been shown to be therapeutically effective in treatment 
of RA or rheumatic disease [95]. As a result, effective IL-6 receptor 
inhibition may provide protection to cardiovascular system in RA 
patients. A recent study demonstrated that in RA female patients, the 
use of tocilizumab improves both endothelial function and arterial 
stiffness (Table 1) [96]. Further, rituximab, a chimeric human/mouse 
monoclonal antibody directed at the CD20 antigen expressed on 
mature B and pre-B cells, has been approved for treatment of moderate 
to severe RA, with MTX, in patients who have inadequate response 
to at least one anti-TNFα inhibitor [97]. In a study involving 49 RA 
patients, the atherogenic index significantly improved (~9%) after 6 
months treatment with rituximab, indicating the beneficial effects on 
lipid profile along with improvement of disease activity [98]. Study 
involving small number of RA patients have also demonstrated that 
rituximab improves carotid atherosclerosis and endothelial function 
(Table 1) [99]. These data suggest the potential benefit of novel biologics 
in preventing CVD in RA patients. 
Conclusion
Clinical and basic science studies consistently demonstrated that 
RA is a condition that accelerates atherosclerosis. Both surrogate 
markers for atherosclerosis and epidemiology studies have confirmed 
the increased risk of CVD in patients with RA. The pathogenesis of 
premature atherosclerosis is likely multifactorial and cannot be entirely 
explained by traditional risk factors. Importantly, therapies that control 
the disease activity hold promise in preventing the development of 
CVD in this group of patients. Future large randomized studies are 
thus important to address and define the therapeutic option in the 
prevention of cardiovascular complication. 
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